Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > 🗞 BIG NEWS SOON --- Going To Explode !!🧨💥🎆🜼🜼🜼🜼

<< Previous

Bullboard Posts

Next >>

Comment by Covid19on Apr 06, 2021 3:48pm

323 Views

Post# 32943320

RE:🗞 BIG NEWS SOON --- Going To Explode !!🧨💥🎆🜼🜼🜼🜼

PowerofNow wrote: Once the BIG NEWS is dropped which will be the preliminary human studies using Nitric Oxide to treat Coronavirus and kill it with an over 80% success rate ... STOCK IS GOING TO SKYROCKET. Estimates from bulls on board are from $1 to as high as $15. I personally have a projection and sell order for $1.35 on two accounts holding Claritas Pharma.

Claritas is currently developing R-107 as a therapy for vaccine-resistant COVID-19, as well as for the treatment of influenza, and other viral diseases. “Prior to initiation of Phase 1 clinical studies in humans, the FDA requires a number of GLP studies to be performed in animals. The positive results in the canine toxicology studies that we are announcing today, together with the positive results in the rodent toxicology studies that we announced last week satisfy the FDA requirements for safety toxicology studies in both species that are a prerequisite for initiating Phase 1 studies in humans and for registration for the market,” stated Robert Farrell, Claritas’ President and CEO.

P.s --- Look at SONA NANOTECH . Hit $16 before the release of any formal product.